4 completed. 4 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 4 | Completed 4 |
Follow Suppuration: new trials by email Literature Review of Suppuration trials Research Report on Suppuration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Infliximab Biosimilar in the Treatment of Resistant Hidradenitis Suppurativa Infliximab-dyyb biosimilar - Hidradenitis Suppurativa | Early Phase 1 | Completed | Services Institute of Medical Sciences, Pakistan | 37 | 2022-10-01 | 2023-11-29 |
| Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa Brodalumab - Hidradenitis Suppurativa, Acne Inversa | Early Phase 1 | Completed | Rockefeller University | 4 | 2021-08-05 | 2022-07-27 |
| Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab Brodalumab - Hidradenitis Suppurativa | Early Phase 1 | Completed | Rockefeller University | 10 | 2019-05-28 | 2020-06-04 |
| Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa secukinumab - Hidradenitis Suppurativa | Early Phase 1 | Completed | Tufts Medical Center | 20 | 2016-07-11 | 2019-06-03 |
Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Hidradenitis (4) · Infections (4) · Skin Diseases (4) · Skin Diseases, Bacterial (4) · Skin Diseases, Infectious (4) · Skin and Connective Tissue Diseases (4) · Sweat Gland Diseases (4)
brodalumab (2) · CT-P13 (1) · secukinumab (1)
Rockefeller University (2) · Services Institute of Medical Sciences, Pakistan (1) · Tufts Medical Center (1)
United States (3) · Pakistan (1)
David Rosmarin, MD (1) · Hira Tariq, FCPS Derma (1) · John W Frew, MD (1) · Yael Renert-Yuval, MD (1)